Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7083245rdf:typepubmed:Citationlld:pubmed
pubmed-article:7083245lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:7083245lifeskim:mentionsumls-concept:C0152018lld:lifeskim
pubmed-article:7083245lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:7083245lifeskim:mentionsumls-concept:C0025716lld:lifeskim
pubmed-article:7083245pubmed:issue6lld:pubmed
pubmed-article:7083245pubmed:dateCreated1982-8-7lld:pubmed
pubmed-article:7083245pubmed:abstractTextTwenty-four patients with epidermoid carcinoma of the esophagus have been treated, in a phase II trial, with methyl-GAG using a weekly schedule. Eighteen patients had received prior chemotherapy with cisplatin-containing combinations. Of 23 evaluable patients, four (17%) had partial remissions, each lasting 2 months. All patients had received prior chemotherapy. Toxic effects were manageable and included mild nausea and vomiting, mucositis, and fatigue. Using this schedule, methyl-GAG had modest activity in esophageal cancer, with acceptable toxicity. Its role in combination chemotherapy remains to be defined.lld:pubmed
pubmed-article:7083245pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7083245pubmed:languageenglld:pubmed
pubmed-article:7083245pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7083245pubmed:citationSubsetIMlld:pubmed
pubmed-article:7083245pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7083245pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7083245pubmed:statusMEDLINElld:pubmed
pubmed-article:7083245pubmed:monthJunlld:pubmed
pubmed-article:7083245pubmed:issn0361-5960lld:pubmed
pubmed-article:7083245pubmed:authorpubmed-author:ChapmanRRlld:pubmed
pubmed-article:7083245pubmed:authorpubmed-author:BainsMMlld:pubmed
pubmed-article:7083245pubmed:authorpubmed-author:GolbeyRRlld:pubmed
pubmed-article:7083245pubmed:authorpubmed-author:KelsenDDlld:pubmed
pubmed-article:7083245pubmed:authorpubmed-author:HeelanRRlld:pubmed
pubmed-article:7083245pubmed:authorpubmed-author:DukemanMMlld:pubmed
pubmed-article:7083245pubmed:issnTypePrintlld:pubmed
pubmed-article:7083245pubmed:volume66lld:pubmed
pubmed-article:7083245pubmed:ownerNLMlld:pubmed
pubmed-article:7083245pubmed:authorsCompleteYlld:pubmed
pubmed-article:7083245pubmed:pagination1427-9lld:pubmed
pubmed-article:7083245pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:7083245pubmed:meshHeadingpubmed-meshheading:7083245-...lld:pubmed
pubmed-article:7083245pubmed:meshHeadingpubmed-meshheading:7083245-...lld:pubmed
pubmed-article:7083245pubmed:meshHeadingpubmed-meshheading:7083245-...lld:pubmed
pubmed-article:7083245pubmed:meshHeadingpubmed-meshheading:7083245-...lld:pubmed
pubmed-article:7083245pubmed:meshHeadingpubmed-meshheading:7083245-...lld:pubmed
pubmed-article:7083245pubmed:meshHeadingpubmed-meshheading:7083245-...lld:pubmed
pubmed-article:7083245pubmed:meshHeadingpubmed-meshheading:7083245-...lld:pubmed
pubmed-article:7083245pubmed:meshHeadingpubmed-meshheading:7083245-...lld:pubmed
pubmed-article:7083245pubmed:meshHeadingpubmed-meshheading:7083245-...lld:pubmed
pubmed-article:7083245pubmed:meshHeadingpubmed-meshheading:7083245-...lld:pubmed
pubmed-article:7083245pubmed:year1982lld:pubmed
pubmed-article:7083245pubmed:articleTitlePhase II study of methyl-GAG in the treatment of esophageal carcinoma.lld:pubmed
pubmed-article:7083245pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7083245pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7083245lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7083245lld:pubmed